The beta-glucuronyl-based prodrug strategy allows for its application on beta-glucuronyl-platinum conjugates.

Abstract

The use of platinum drugs in antitumour therapy is well established. An important drawback of these chemotherapeutics is the lack of selectivity for tumour cells, usually resulting in severe toxic side effects. A glucuronyl-platinum conjugate was designed and synthesised to test the compatibility of platinum compounds with beta-glucuronidase-based prodrug… (More)

Topics

Cite this paper

@article{Tromp2004TheBP, title={The beta-glucuronyl-based prodrug strategy allows for its application on beta-glucuronyl-platinum conjugates.}, author={Reynier A Tromp and Stella S G E van Boom and C Marco Timmers and S W A M van Zutphen and Gijsbert A. van der Marel and Herman S Overkleeft and Jacques H. van Boom and Jan Reedijk}, journal={Bioorganic & medicinal chemistry letters}, year={2004}, volume={14 16}, pages={4273-6} }